Clinical trial
A 24 Week Phase Ib/II, Multicenter, Randomized, Controlled, Parallel Group, Dose Ranging Study With a 24 Week Follow-up to Evaluate Safety and Potential Efficacy of 2 Doses (60, 180 µg/ml) of rhNGF Solution vs Vehicle in Patients With RP.
NCT02110225 is registered in ClinicalTrials.gov with Dompé Farmaceutici S.p.A as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A 24 Week Phase Ib/II, Multicenter, Randomized, Controlled, Parallel Group, Dose Ranging Study With a 24 Week Follow-up to Evaluate Safety and Potential Efficacy of 2 Doses (60, 180 µg/ml) of rhNGF Solution vs Vehicle in Patients With RP.
- Lead sponsor
- Dompé Farmaceutici S.p.A
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- January 31, 2014
- Completion date
- November 30, 2015
- Enrollment
- 50 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.